Measurements	O
:	O

Symptoms	O
and	O
severity	O
at	O
baseline	O
and	O
then	O
at	O
days	O
3	O
,	O
5	O
,	O
10	O
,	O
and	O
14	O
using	O
a	O
10	O
-	O
point	O
visual	O
analogue	O
scale	O
.	O

The	O
primary	O
end	O
point	O
was	O
change	O
in	O
overall	O
symptom	O
severity	O
over	O
14	O
days	O
.	O

Study	O
End	O
Points	O

The	O
initial	O
primary	O
outcome	O
was	O
an	O
ordinal	O
outcome	O
by	B-TimeFrame
day	I-TimeFrame
14	I-TimeFrame
of	O
not	B-PrimaryOutcome
hospitalized	I-PrimaryOutcome
,	I-PrimaryOutcome
hospitalized	I-PrimaryOutcome
,	I-PrimaryOutcome
or	I-PrimaryOutcome
intensive	I-PrimaryOutcome
care	I-PrimaryOutcome
unit	I-PrimaryOutcome
stay	I-PrimaryOutcome
or	I-PrimaryOutcome
death	I-PrimaryOutcome
.	O

Secondary	O
end	O
points	O
were	O
symptom	B-SecondaryOutcome
severity	I-SecondaryOutcome
at	B-TimeFrame
day	I-TimeFrame
5	I-TimeFrame
and	I-TimeFrame
day	I-TimeFrame
14	I-TimeFrame
by	O
10	O
-	O
point	O
visual	O
analogue	O
scale	O
,	O
nominal	B-SecondaryOutcome
incidence	I-SecondaryOutcome
of	I-SecondaryOutcome
all	I-SecondaryOutcome
hospitalizations	I-SecondaryOutcome
and	I-SecondaryOutcome
deaths	I-SecondaryOutcome
,	O
and	O
incidence	B-SecondaryOutcome
of	I-SecondaryOutcome
study	I-SecondaryOutcome
medicine	I-SecondaryOutcome
withdrawal	I-SecondaryOutcome
.	O

Changes	O
in	O
End	O
Point	O
and	O
Sample	O
Sizes	O

Before	O
the	O
first	O
interim	O
analysis	O
on	O
24	O
April	O
2020	O
,	O
it	O
became	O
apparent	O
that	O
the	O
pooled	O
event	O
rate	O
of	O
hospitalization	O
or	O
death	O
was	O
substantially	O
lower	O
than	O
our	O
initial	O
10	O
%	O
expectation	O
(	O
original	O
sample	O
size	O
calculations	O
as	O
described	O
in	O
Statistical	O
Analysis	O
section	O
)	O
.	O

Without	O
unblinding	O
of	O
treatment	O
allocation	O
or	O
analysis	O
of	O
the	O
data	O
,	O
the	O
principal	O
investigator	O
proposed	O
to	O
the	O
data	O
and	O
safety	O
monitoring	O
board	O
(	O
DSMB	O
)	O
that	O
we	O
modify	O
the	O
primary	O
end	O
point	O
to	O
the	O
change	B-PrimaryOutcome
in	I-PrimaryOutcome
overall	I-PrimaryOutcome
symptom	I-PrimaryOutcome
severity	I-PrimaryOutcome
over	B-TimeFrame
14	I-TimeFrame
days	I-TimeFrame
as	O
longitudinally	O
measured	O
on	O
a	O
10	O
-	O
point	O
visual	O
analogue	O
scale	O
.	O

The	O
DSMB	O
approved	O
the	O
change	O
on	O
24	O
April	O
2020	O
.	O

The	O
change	O
was	O
necessary	O
because	O
the	O
low	O
event	O
rate	O
of	O
hospitalizations	O
or	O
deaths	O
in	O
the	O
trial	O
would	O
have	O
required	O
increasing	O
the	O
sample	O
size	O
to	O
6000	O
participants	O
,	O
which	O
was	O
not	O
attainable	O
.	O

With	O
enrollment	O
of	O
at	O
least	O
200	O
participants	O
per	O
group	O
,	O
we	O
determined	O
that	O
the	O
revised	O
trial	O
would	O
have	O
90	O
%	O
power	O
(	O
with	O
a	O
2	O
-	O
sided	O
Î±	O
level	O
of	O
0	O
.	O
05	O
)	O
to	O
detect	O
a	O
statistically	O
significant	O
difference	O
between	O
the	O
groups	O
for	O
a	O
change	O
in	O
symptom	O
severity	O
score	O
as	O
small	O
as	O
0	O
.	O
25	O
point	O
on	O
the	O
10	O
-	O
point	O
visual	O
analogue	O
scale	O
.	O

The	O
trial	O
halted	O
at	O
the	O
second	O
DSMB	O
meeting	O
on	O
6	O
May	O
2020	O
,	O
when	O
the	O
DSMB	O
determined	O
that	O
sufficient	O
statistical	O
power	O
had	O
been	O
achieved	O
to	O
evaluate	O
the	O
primary	O
outcome	O
.	O

Outcomes	O
and	O
Follow	O
-	O
up	O

We	O
collected	O
self	O
-	O
reported	O
survey	O
data	O
using	O
the	O
Research	O
Electronic	O
Data	O
Capture	O
(	O
REDCap	O
)	O
system	O
(	O
13	O
)	O
.	O

We	O
e	O
-	O
mailed	O
participants	O
follow	O
-	O
up	O
surveys	O
on	B-TimeFrame
days	I-TimeFrame
1	I-TimeFrame
(	I-TimeFrame
medication	I-TimeFrame
start	I-TimeFrame
date	I-TimeFrame
)	I-TimeFrame
,	I-TimeFrame
3	I-TimeFrame
,	I-TimeFrame
5	I-TimeFrame
(	I-TimeFrame
medication	I-TimeFrame
stop	I-TimeFrame
date	I-TimeFrame
)	I-TimeFrame
,	I-TimeFrame
10	I-TimeFrame
,	I-TimeFrame
and	I-TimeFrame
14	I-TimeFrame
to	O
assess	O
study	O
medication	B-OtherOutcome
adherence	I-OtherOutcome
,	O
adverse	B-OtherOutcome
effects	I-OtherOutcome
,	O
presence	B-OtherOutcome
and	I-OtherOutcome
severity	I-OtherOutcome
of	I-OtherOutcome
COVID	I-OtherOutcome
-	I-OtherOutcome
19	I-OtherOutcome
symptoms	I-OtherOutcome
,	O
COVID	B-OtherOutcome
-	I-OtherOutcome
19	I-OtherOutcome
test	I-OtherOutcome
results	I-OtherOutcome
,	O
and	O
hospitalization	B-OtherOutcome
status	I-OtherOutcome
.	O

If	O
participants	O
were	O
hospitalized	O
within	O
14	O
days	O
,	O
we	O
continued	O
follow	O
-	O
up	O
past	O
study	O
completion	O
to	O
assess	O
outcomes	O
.	O

We	O
assessed	O
symptom	O
severity	O
on	O
a	O
10	O
-	O
point	O
visual	O
analogue	O
scale	O
,	O
where	O
0	O
indicated	O
no	O
symptoms	O
and	O
10	O
indicated	O
severe	O
symptoms	O
(	O
Supplement	O
)	O
.	O

Medication	B-OtherOutcome
-	I-OtherOutcome
related	I-OtherOutcome
adverse	I-OtherOutcome
events	I-OtherOutcome
were	O
collected	O
with	O
directed	O
questioning	O
on	O
the	O
most	O
common	O
adverse	O
effects	O
and	O
an	O
open	O
-	O
ended	O
free	O
-	O
text	O
field	O
.	O

For	O
participants	O
who	O
did	O
not	O
respond	O
to	O
follow	O
-	O
up	O
surveys	O
,	O
investigators	O
used	O
text	O
messages	O
,	O
e	O
-	O
mails	O
,	O
or	O
telephone	O
calls	O
to	O
ascertain	O
outcomes	O
from	O
them	O
or	O
their	O
designated	O
third	O
-	O
party	O
contacts	O
.	O

If	O
this	O
was	O
unsuccessful	O
,	O
investigators	O
searched	O
the	O
internet	O
for	O
obituaries	O
or	O
other	O
evidence	O
of	O
vital	O
status	O
.	O

